KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Biotechnology

Healthcare
$27.00 +0.00%

+$0.00 today

Market cap
$1.44B
Beta
-0.11
P/E (TTM)
-9.9
EPS (TTM)
-$2.74
52W Low $9.83High $27.00

Volume 4.26M

Average 3.47M

Income Statement

Follow revenue through to earnings.

Revenue

$73.62M

FY 2026 · Annual

Operating Income

-$171.84M

FY 2026 · Annual

Net Income

-$164.29M

FY 2026 · Annual

Income Statement

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Dec 2025
Revenue000073.62M
Cost of Revenue0086.17M06.08M
Gross Profit00(86.17M)067.54M
Gross Margin————91.7%
Research & Development70.17M80.28M86.17M71.71M55.64M
Selling, General & Admin26.45M30.6M54.28M116.29M183.74M
Operating Expenses96.61M110.87M54.28M188M239.38M
Depreciation & Amortization564K718K816K941K1.45M
EBITDA(80.75M)(94.37M)(134.28M)(173.33M)(150.62M)
EBITDA Margin————-204.6%
Operating Income(96.61M)(110.87M)(140.45M)(188M)(171.84M)
Operating Margin————-233.4%
Interest Income1.09M2.23M3.9M6.44M8.68M
Interest Expense0005.79M19.34M
Other Income / Expenses14.27M17.96M5.35M7.94M420K
Income Before Tax(82.34M)(92.91M)(135.1M)(180.05M)(171.42M)
Pre-Tax Margin————-232.9%
Income Tax Expense00(8.45M)3.39M(7.13M)
Net Income(82.34M)(92.91M)(126.64M)(183.44M)(164.29M)
Net Margin————-223.2%
EPS (Basic)(3.36)(3.33)(3.44)(3.69)(3.23)
EPS (Diluted)(3.36)(3.33)(3.44)(3.69)(3.23)
Weighted Avg Shares24.47M27.89M36.79M49.65M50.9M
Weighted Avg Shares (Diluted)24.47M27.89M36.79M49.65M50.9M

KALV Earnings Waterfall · TTM

NASDAQ:KALV · Revenue to Net Income

Key Ratios

EPS$-3.23
Gross Margin83.6%
Net Margin-1160.5%
P/E Ratio-15.5
P/S Ratio147.8

Analysis

$115.9M of revenue converted into -$138.4M of net income for the selected period. Gross margin is 83.6% and net margin is -1160.5%, showing how much revenue survives after costs and taxes. EPS is $-3.23, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportJun 11, 2026
4Statement of changes in beneficial ownershipJun 11, 2026
4Statement of changes in beneficial ownershipJun 11, 2026
4Statement of changes in beneficial ownershipJun 11, 2026
4Statement of changes in beneficial ownershipJun 11, 2026

How much revenue does KALV generate?

KalVista Pharmaceuticals, Inc. (KALV) reported $73.62M of revenue in fiscal 2026.

Is KALV profitable?

KalVista Pharmaceuticals, Inc. (KALV) reported -$164.29M of net income, with a net margin of -223.2%.